Sujata M Shanbhag1, Anders M Greve1,2, Thor Aspelund3,4, Erik B Schelbert1,5, J Jane Cao1,6, Ragnar Danielsen4, Guðmundur Þorgeirsson4, Sigurður Sigurðsson3, Guðný Eiríksdóttir3, Tamara B Harris7, Lenore J Launer7, Vilmundur Guðnason3,4, Andrew E Arai1. 1. Department of Health and Human Services, National Heart, Lung, and Blood Institute, National Institutes of Health, Building 10, Room B1D416, MSC 1061, 10 Center Dr., Bethesda, MD, USA. 2. Department of Clinical Biochemistry, Rigshospitalet, 9 Blegdamsvej, Copenhagen, Denmark. 3. Hjartavernd (Icelandic Heart Association), Holtasmari 1, Kopavogur, Iceland. 4. University of Iceland, Sæmundargata 2, Reykjavik, Iceland. 5. University of Pittsburgh Medical Center, Heart and Vascular Institute, 200 Lothrop St., Ste. A349, Pittsburgh, PA, USA. 6. St. Francis Hospital, The heart Center, State University of New York at Stony Brook, 100 Port Washington Blvd, Roslyn, NY, USA. 7. Laboratory of Epidemiology & Population Science, National Institute on Aging, National Institutes of Health, Department of Health and Human Services, GWY Bldg Rm 2N300, 7201 Wisconsin Ave, Bethesda, MD, USA.
Abstract
Aims: Non-ischaemic cardiomyopathies (NICM) can cause heart failure and death. Cardiac magnetic resonance (CMR) detects myocardial scar/fibrosis associated with myocardial infarction (MI) and NICM with late gadolinium enhancement (LGE). The aim of this study was to determine the prevalence and prognosis of ischaemic and non-ischaemic myocardial fibrosis in a community-based sample of older adults. Methods and results: The ICELAND-MI cohort, a substudy of the Age, Gene/Environment Susceptibility Reykjavik (AGES-Reykjavik) study, provided a well-characterized population of 900 subjects after excluding subjects with pre-existing heart failure. Late gadolinium enhancement CMR divided subjects into four groups: MI (n = 211), major (n = 54) non-ischaemic fibrosis (well-established, classic patterns, associated with myocarditis, infiltrative cardiomyopathies, or pathological hypertrophy), minor (n = 238) non-ischaemic fibrosis (remaining localized patterns not meeting major criteria), and a no LGE (n = 397) reference group. The primary outcome was time to death or first heart failure hospitalization. During a median follow-up of 5.8 years, 192 composite events occurred (115 deaths and 77 hospitalizations for incident heart failure). After inverse probability weighting, major non-ischaemic fibrosis [hazard ratio (HR) 3.2, P < 0.001] remained independently associated with the primary endpoint, while MI (HR 1.4, P = 0.10) and minor non-ischaemic LGE (HR 1.2, P = 0.39) did not. Major non-ischaemic fibrosis was associated with a poorer outcome than MI (HR = 2.3, P = 0.001) in the adjusted analysis. Conclusion: Major non-ischaemic patterns of myocardial fibrosis portended worse prognosis than no fibrosis/scar in an older community-based cohort. Traditional risk factors largely accounted for the effect of MI and minor non-ischaemic LGE.
Aims: Non-ischaemic cardiomyopathies (NICM) can cause heart failure and death. Cardiac magnetic resonance (CMR) detects myocardial scar/fibrosis associated with myocardial infarction (MI) and NICM with late gadolinium enhancement (LGE). The aim of this study was to determine the prevalence and prognosis of ischaemic and non-ischaemic myocardial fibrosis in a community-based sample of older adults. Methods and results: The ICELAND-MI cohort, a substudy of the Age, Gene/Environment Susceptibility Reykjavik (AGES-Reykjavik) study, provided a well-characterized population of 900 subjects after excluding subjects with pre-existing heart failure. Late gadolinium enhancement CMR divided subjects into four groups: MI (n = 211), major (n = 54) non-ischaemic fibrosis (well-established, classic patterns, associated with myocarditis, infiltrative cardiomyopathies, or pathological hypertrophy), minor (n = 238) non-ischaemic fibrosis (remaining localized patterns not meeting major criteria), and a no LGE (n = 397) reference group. The primary outcome was time to death or first heart failure hospitalization. During a median follow-up of 5.8 years, 192 composite events occurred (115 deaths and 77 hospitalizations for incident heart failure). After inverse probability weighting, major non-ischaemic fibrosis [hazard ratio (HR) 3.2, P < 0.001] remained independently associated with the primary endpoint, while MI (HR 1.4, P = 0.10) and minor non-ischaemic LGE (HR 1.2, P = 0.39) did not. Major non-ischaemic fibrosis was associated with a poorer outcome than MI (HR = 2.3, P = 0.001) in the adjusted analysis. Conclusion: Major non-ischaemic patterns of myocardial fibrosis portended worse prognosis than no fibrosis/scar in an older community-based cohort. Traditional risk factors largely accounted for the effect of MI and minor non-ischaemic LGE.
Authors: William M Bradlow; Ravi Assomull; Philip J Kilner; J Simon R Gibbs; Mary N Sheppard; Raad H Mohiaddin Journal: Circ Cardiovasc Imaging Date: 2010-07 Impact factor: 7.792
Authors: Eddy Barasch; John S Gottdiener; Emily K Marino Larsen; Paulo H M Chaves; Anne B Newman; Teri A Manolio Journal: Am Heart J Date: 2006-01 Impact factor: 4.749
Authors: Barry J Maron; Jeffrey A Towbin; Gaetano Thiene; Charles Antzelevitch; Domenico Corrado; Donna Arnett; Arthur J Moss; Christine E Seidman; James B Young Journal: Circulation Date: 2006-03-27 Impact factor: 29.690
Authors: R J Kim; D S Fieno; T B Parrish; K Harris; E L Chen; O Simonetti; J Bundy; J P Finn; F J Klocke; R M Judd Journal: Circulation Date: 1999-11-09 Impact factor: 29.690
Authors: Li-Yueh Hsu; W Patricia Ingkanisorn; Peter Kellman; Anthony H Aletras; Andrew E Arai Journal: J Magn Reson Imaging Date: 2006-03 Impact factor: 4.813
Authors: Alana A Lewis; Colby R Ayers; Elizabeth Selvin; Ian Neeland; Christie M Ballantyne; Vijay Nambi; Ambarish Pandey; Tiffany M Powell-Wiley; Mark H Drazner; Mercedes R Carnethon; Jarett D Berry; Stephen L Seliger; Christopher R DeFilippi; James A de Lemos Journal: Circulation Date: 2020-01-14 Impact factor: 29.690
Authors: Andrew J Morrow; Robert Sykes; Alasdair McIntosh; Anna Kamdar; Catherine Bagot; Hannah K Bayes; Kevin G Blyth; Michael Briscoe; Heerajnarain Bulluck; David Carrick; Colin Church; David Corcoran; Iain Findlay; Vivienne B Gibson; Lynsey Gillespie; Douglas Grieve; Pauline Hall Barrientos; Antonia Ho; Ninian N Lang; Vera Lennie; David J Lowe; Peter W Macfarlane; Patrick B Mark; Kaitlin J Mayne; Alex McConnachie; Ross McGeoch; Christopher McGinley; Connor McKee; Sabrina Nordin; Alexander Payne; Alastair J Rankin; Keith E Robertson; Giles Roditi; Nicola Ryan; Naveed Sattar; Sarah Allwood-Spiers; David Stobo; Rhian M Touyz; Gruschen Veldtman; Stuart Watkins; Sarah Weeden; Robin A Weir; Paul Welsh; Ryan Wereski; Kenneth Mangion; Colin Berry Journal: Nat Med Date: 2022-05-23 Impact factor: 87.241
Authors: Carsten Tschöpe; Sophie Van Linthout; Sebastian Jäger; Robert Arndt; Tobias Trippel; Irene Müller; Ahmed Elsanhoury; Susanne Rutschow; Stefan D Anker; Heinz-Peter Schultheiss; Matthias Pauschinger; Frank Spillmann; Kathleen Pappritz Journal: ESC Heart Fail Date: 2020-07-14
Authors: Katherine C Wu; Sabina A Haberlen; Michael W Plankey; Frank J Palella; Damani A Piggott; Gregory D Kirk; Joseph B Margolick; Wendy S Post Journal: Eur Heart J Cardiovasc Imaging Date: 2021-07-20 Impact factor: 6.875